{
  "docId": "019de076-b731-71da-a78f-007719e300bb",
  "docSlug": "1616e8b22ac58e7f024f1153201d610f",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 42,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 51,
  "notes": "Swimmer plot visualization of clinical trial patient outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/22",
  "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb",
  "deckJsonHref": "/decks/019de076-b731-71da-a78f-007719e300bb.json",
  "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.65,
        "x": 0.08,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Swimmer plot of patient treatment duration",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2492aa59-d5fc-431a-a97d-ae2a37831101",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.058,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "Data as of 8 August 2023, for response-evaluable patients with NSCLC. PD, progressive disease; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fffc96db-1734-4996-8ee4-59e72276a8cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.655,
        "y": 0.25
      },
      "kind": "legend",
      "text": "Legend for patient cohorts and clinical events (PR, PD, Ongoing)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a156fa60-fbf3-4d71-8b43-7db1e57dd936",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.45,
        "x": 0.465,
        "y": 0.615
      },
      "kind": "list",
      "text": "All patients with RECIST 1.1 tumor response remain on treatment without disease progression; 67% (34/51) response-evaluable patients continue treatment; Median (range) duration of treatment: 3.4 (0.3, 12.3) months; Median (range) time to response: 6.1 (5.1, 12.3) weeks",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45865a2d-8d6e-431f-999f-1ac8ac974347",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.058,
        "y": 0.115
      },
      "kind": "title",
      "text": "Time on Treatment: Sustained Duration with Follow-up Ongoing",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0278b00d-3c8c-4491-a8b8-80ecaa2d5391",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}